ARTV – artiva biotherapeutics, inc. (US:NASDAQ)

News

Artiva Biotherapeutics to Participate in the 2024 Cantor Fitzgerald Global Healthcare Conference
Artiva Biotherapeutics, Inc. (NASDAQ: ARTV) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $18.00 price target on the stock.
Artiva Biotherapeutics, Inc. (NASDAQ: ARTV) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $23.00 price target on the stock.
Artiva Biotherapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights [Yahoo! Finance]
Artiva Biotherapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights
Show more
Live Event: Join our next subscriber-only event: "The Data Driven Investor"
Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com